Improving cancer immunotherapy by targeting tumor-induced immune suppression.
about
Immune Reactivation by Cell-Free Fetal DNA in Healthy Pregnancies Re-Purposed to Target Tumors: Novel Checkpoint Inhibition in Cancer TherapeuticsHost matrix modulation by tumor exosomes promotes motility and invasiveness.Mechanisms and applications of interleukins in cancer immunotherapy.Big opportunities for small molecules in immuno-oncology.The immune response to tumors as a tool toward immunotherapy.Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell linesChemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors.Regulating Tumor Myeloid-Derived Suppressor Cells by MicroRNAs.The pro-metastatic role of bone marrow-derived cells: a focus on MSCs and regulatory T cellsCancer immunotherapy: Progress and challenges in the clinical setting.Intratumoral delivery of low doses of anti-CD40 mAb combined with monophosphoryl lipid a induces local and systemic antitumor effects in immunocompetent and T cell-deficient mice.Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer.Circulating Myeloid-Derived Suppressor Cells Predict Differentiated Thyroid Cancer Diagnosis and ExtentA Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors.Lysophosphatidic acid inhibits CD8 T cell activation and control of tumor progression.Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapyImmunotherapy-induced CD8+ T cells instigate immune suppression in the tumor.Variation of tumor-infiltrating lymphocytes in human cancers: controversy on clinical significance.Immune suppression: the hallmark of myeloid derived suppressor cells.Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines.Immune modulation by chemotherapy or immunotherapy to enhance cancer vaccines.Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.Down-regulation of LPA receptor 5 contributes to aberrant LPA signalling in EBV-associated nasopharyngeal carcinoma.Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathiesMreg Activity in Tumor Response to Photodynamic Therapy and Photodynamic Therapy-Generated Cancer Vaccines.Effect of dietary selenium and cancer cell xenograft on peripheral T and B lymphocytes in adult nude mice.Strategies to reverse melanoma-induced T-cell dysfunctionImmunoregulatory Cell Depletion Improves the Efficacy of Photodynamic Therapy-Generated Cancer Vaccines.PD-L1+MDSCs are increased in HCC patients and induced by soluble factor in the tumor microenvironment.Upregulation of CD200 is associated with Foxp3+ regulatory T cell expansion and disease progression in acute myeloid leukemia.Notch1 signaling in melanoma cells promoted tumor-induced immunosuppression via upregulation of TGF-β1.Adaptive Resistance to Cancer Immunotherapy.The dawn of "immune-revolution" in children: early experiences with checkpoint inhibitors in childhood malignancies.T cell responses to tumor: how dominant assumptions on immune activity led to a neglect of pathological functions, and how evolutionary considerations can help identify testable hypotheses for improving immunotherapy.Reduction of myeloid-derived suppressor cells reinforces the anti-solid tumor effect of recipient leukocyte infusion in murine neuroblastoma-bearing allogeneic bone marrow chimeras.Aneustat (OMN54) has aerobic glycolysis-inhibitory activity and also immunomodulatory activity as indicated by a first-generation PDX prostate cancer model.Liver sinusoidal endothelial cells contribute to CD8 T cell tolerance toward circulating carcinoembryonic antigen in mice.Systemic administration of a TLR7 agonist attenuates regulatory T cells by dendritic cell modification and overcomes resistance to PD-L1 blockade therapy.Optimizing Tumor Microenvironment for Cancer Immunotherapy: β-Glucan-Based Nanoparticles.CD39/CD73 upregulation on myeloid-derived suppressor cells via TGF-β-mTOR-HIF-1 signaling in patients with non-small cell lung cancer.
P2860
Q26784480-B6FC7A82-88E2-4DF5-B6F3-0B231A64E4BCQ30541999-32A3E5F1-798D-44B8-B275-521D496EC200Q34458290-B10E88BA-47EC-4DB4-833C-2770DC176228Q34487689-CDA35008-ACE4-470C-B99C-C5619B5F2FE7Q34634545-29A61C1E-2112-4E60-B0EE-B84A98525B58Q35082018-0D366B9C-F841-419C-9333-0A5647FE94BDQ35580479-3D267104-B119-4224-A12A-0D72B1EA5ACCQ35633856-AD8FD703-F638-43F0-BA7F-59C8F676900BQ35931795-65FB86B0-51CE-4304-BF21-CA18D426BA35Q36184314-56AC3418-37EB-48C7-8E82-48CB2866DB7FQ36465489-45A29DEF-3272-4627-AFBD-ACACCD36A929Q36567697-4E1BA358-D239-483E-BD48-188453A17636Q36683267-31982370-9A8B-4197-8F25-55672887078FQ36709308-CEEE02D1-BA03-4AE8-8AB7-A059AAD0431BQ37486804-5BC58731-7BBF-4851-951F-37AC715A38A7Q37543402-99D18E2C-BA02-4DF1-88DF-CBDF3E7EF873Q37690444-5209583A-EFC2-4FD0-AE40-4C89DFFEFC50Q37945304-183C13F8-78F4-4CD9-B7E4-6CB5F8B01AE9Q38047049-51D740E6-C92F-43E4-9121-375F1BA7F752Q38154151-93227C58-8407-434F-B83A-6525205DB592Q38161367-EFC2EACD-FFB4-4EF0-96A2-6B84D646358EQ38646993-1118D47B-6DE3-4718-BEEB-C74A65E8E689Q38949843-A37BA961-3E6E-422B-A5E0-85A7F6018F99Q39010566-93716808-D607-4D8B-ACFF-42BE006C20B7Q39277701-6F0365C6-7DC7-4807-A27E-418677985F49Q39454155-C3E8300F-34A5-4F00-8376-F89E169A957CQ40785322-EE1B3A4D-A063-46BF-B040-78657323754DQ41121965-07C0BEB4-DEC9-43F9-80D2-788CF66525F0Q42264428-931106BB-86B0-4B7F-BDFF-2762CBE43878Q46952293-2535D6C9-914E-46A4-AA33-DB922B02FA3AQ47169624-EDC007AF-D385-49FE-886D-6B397AFB252AQ47252744-6076C8C1-256A-4767-AEF5-4386A6A5CD4CQ47724505-91880545-8636-4241-B0C9-4388145F5FE7Q48238886-9EDEFB83-A95A-40FB-9EDA-A20C800F0C89Q48312537-85DE97BD-2C5A-4A8C-9D53-76DEFC3C65FDQ50020665-05FE2600-471E-4504-901F-0650CF426354Q50953925-A838BC74-7D2C-4F6E-8524-2C0DC142F4B5Q51736282-52342E4D-406B-4B2F-A50E-8AFCD04D1572Q52657150-83A4C755-AD26-4200-8914-315E85A77194Q52763511-2FD5840A-ABAD-4B79-914E-E9BB661DDC2B
P2860
Improving cancer immunotherapy by targeting tumor-induced immune suppression.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Improving cancer immunotherapy by targeting tumor-induced immune suppression.
@en
Improving cancer immunotherapy by targeting tumor-induced immune suppression.
@nl
type
label
Improving cancer immunotherapy by targeting tumor-induced immune suppression.
@en
Improving cancer immunotherapy by targeting tumor-induced immune suppression.
@nl
prefLabel
Improving cancer immunotherapy by targeting tumor-induced immune suppression.
@en
Improving cancer immunotherapy by targeting tumor-induced immune suppression.
@nl
P2860
P1476
Improving cancer immunotherapy by targeting tumor-induced immune suppression.
@en
P2093
Trina J Stewart
P2860
P2888
P304
P356
10.1007/S10555-011-9280-5
P577
2011-03-01T00:00:00Z